Abstract
Patients with interstitial lung disease (ILD) suffer from poor quality of life and increased mortality. The poor quality of life is multifactorial, attributable in large part to respiratory symptoms and limitations, medication side effects, and the psychiatric effects of chronic illness. Sleep is affected by these same stresses, resulting in poor sleep quality and sleep disordered breathing. Sleep fragmentation, arousals, and Stage N1 sleep are all increased in patients with ILD. Sleep disordered breathing, in the form of nocturnal hypoxia and obstructive sleep apnea, is common in these patients as well. These sleep disorders are associated with indices of poor quality of life and excessive daytime sleepiness, and may be targets of therapy for the overall management of patients with ILD.
Keywords: Interstitial lung disease, restrictive lung disease, idiopathic pulmonary fibrosis, sleep, sleep disordered breathing
Current Respiratory Medicine Reviews
Title: Sleep in Interstitial Lung Disease
Volume: 5 Issue: 4
Author(s): Vidya Krishnan
Affiliation:
Keywords: Interstitial lung disease, restrictive lung disease, idiopathic pulmonary fibrosis, sleep, sleep disordered breathing
Abstract: Patients with interstitial lung disease (ILD) suffer from poor quality of life and increased mortality. The poor quality of life is multifactorial, attributable in large part to respiratory symptoms and limitations, medication side effects, and the psychiatric effects of chronic illness. Sleep is affected by these same stresses, resulting in poor sleep quality and sleep disordered breathing. Sleep fragmentation, arousals, and Stage N1 sleep are all increased in patients with ILD. Sleep disordered breathing, in the form of nocturnal hypoxia and obstructive sleep apnea, is common in these patients as well. These sleep disorders are associated with indices of poor quality of life and excessive daytime sleepiness, and may be targets of therapy for the overall management of patients with ILD.
Export Options
About this article
Cite this article as:
Krishnan Vidya, Sleep in Interstitial Lung Disease, Current Respiratory Medicine Reviews 2009; 5 (4) . https://dx.doi.org/10.2174/157339809790112410
DOI https://dx.doi.org/10.2174/157339809790112410 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART II
Current Neuropharmacology Kynurenines in the Central Nervous System: Recent Developments
Central Nervous System Agents in Medicinal Chemistry Novel Therapies for Schizophrenia: Understanding the Glutamatergic Synapse and Potential Targets for Altering N-methyl-D-aspartate Neurotransmission
Recent Patents on CNS Drug Discovery (Discontinued) Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease
Current Drug Metabolism Natural Compounds Used as Therapies Targeting to Amyotrophic Lateral Sclerosis
Current Pharmaceutical Biotechnology Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Receptor Heteromers in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
CNS & Neurological Disorders - Drug Targets Role of Dopamine Signaling in Drug Addiction
Current Topics in Medicinal Chemistry Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Current Pharmaceutical Design Levodopa in Parkinson’s Disease: Current Status and Future Developments
Current Neuropharmacology Serotonin 5-HT<sub>1A</sub> Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs
Current Pharmaceutical Design A Comparison Between Quetiapine and Aripiprazole for Treatment of Schizophrenia: A Double Blind Contrast
Current Psychopharmacology Gene Therapy for Parkinsons Disease: Progress and Challenges
Current Gene Therapy Blocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Recent Advances on Horizontal Lower Limb Rehabilitation Robot
Recent Patents on Mechanical Engineering Lower K<sub>V</sub>7.5 Potassium Channel Subunit Expression in an Animal Model of Paroxysmal Dystonia
CNS & Neurological Disorders - Drug Targets Extracellular Matrix in Atherosclerosis: Hyaluronan and Proteoglycans Insights
Current Medicinal Chemistry Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets Targeting the Progression of Parkinsons Disease
Current Neuropharmacology Advances in Mucomodulator Therapy for Treatment of Excess Airway Mucus in Patients with Asthma, Chronic Obstructive Pulmonary Disease and Cystic Fibrosis
Recent Patents on Materials Science